Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +49.51%
#3 Helium Helium +48.71%
#4 Pons Pons +43.17%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +31.04%
#7 Collector Crypt Collector Crypt +24.28%
#8 Nillion Nillion +19.84%
#9 龙虾 (Lobster) 龙虾 (Lobster) +19.38%
#10 o1.exchange o1.exchange +18.11%
Coin of the day
GEKKO GEKKO
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
Classement en actions #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Prix de l'action
$24.98
Dernière synchronisation: 2023-04-27
Capitalisation boursière
$1.01B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Provention Bio, Inc. (PRVB)

Catégorie

Healthcare
Nombre d'actions en circulation pour Provention Bio, Inc. (PRVB)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Provention Bio, Inc., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Provention Bio, Inc. (PRVB) de 2026 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
Pas assez de données pour les dates fournies.
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH